1,3-二氢-4-(2-羟乙基)-2H-吲哚-2-酮 | 139122-19-3

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1,3-二氢-4-(2-羟乙基)-2H-吲哚-2-酮
• 中文别名: 4-(2'-羟乙基)-2-吲哚酮；4-(2-羟乙基)氧化吲哚；4-(2-羟乙基)氧化吲哚(罗匹尼罗中间体)；罗匹尼罗中间体五；罗匹尼罗中间体 五
• 英文名称: 4-(2-hydroxyethyl)indolin-2-one
• 英文别名: 4-(2'-hydroxyethyl)-1,3-dihydro-2H-indol-2-one；4-(2-hydroxyethyl)-1,3-dihydro-2H-indolin-2-one；4-(2-hydroxyethyl)-1,3-dihydroindol-2-one
• CAS: 139122-19-3
• 化学式: C₁₀H₁₁NO₂
• mdl: MFCD07782133
• 分子量: 177.203
• InChiKey: QRTHVOUKWCEPKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  148-150°C
• 沸点：
  390.0±42.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R42/43
• 海关编码：
  2933790090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 冰箱 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(2-Hydroxyethyl)oxyindole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(2-Hydroxyethyl)oxyindole
CAS number: 139122-19-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11NO2
Molecular weight: 177.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二氢-4-(2-羟乙基)-2H-吲哚-2-酮 在 吡啶 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 6.0h， 生成 累匹利洛
  参考文献：
  名称：

  罗匹尼罗的一些合成方法（sk＆f 101468-a）：一种有效的多巴胺受体激动剂

  摘要：

  描述了三种新的制备罗匹尼罗的途径（SK＆F 101468-A，1），每个途径都涉及从β-硝基苯乙烯制备3型3-氯代吲哚中间体这一关键步骤。还描述了作为酯的直接前体的磺酸酯17a-c相对于溴化物11的优越性。

  DOI：

  10.1002/jhet.5570320334
• 作为产物：
  描述：

  4-(2’-溴乙基)-3-氯-1,3-二氯-2-吲哚酮 在 palladium on activated charcoal 盐酸 、 sodium hypophosphite 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 27.08h， 生成 1,3-二氢-4-(2-羟乙基)-2H-吲哚-2-酮
  参考文献：
  名称：

  罗匹尼罗的一些合成方法（sk＆f 101468-a）：一种有效的多巴胺受体激动剂

  摘要：

  描述了三种新的制备罗匹尼罗的途径（SK＆F 101468-A，1），每个途径都涉及从β-硝基苯乙烯制备3型3-氯代吲哚中间体这一关键步骤。还描述了作为酯的直接前体的磺酸酯17a-c相对于溴化物11的优越性。

  DOI：

  10.1002/jhet.5570320334

文献信息

• Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands
  作者：Benhua Zhou、Kwon Ho Hong、Min Ji、Jin Cai

  DOI：10.1111/cbdd.13324

  日期：2018.9

  evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined (using the method of radioligand binding assay). Compared to comparator agent BP897, compounds 2a and 2c were found to demonstrate a considerable binding affinity and selectivity for D3 receptor, and especially compound 2h was similarly potent and more selective D3R ligand than

  设计，合成和评估了两个系列的杂合类似物，作为多巴胺D3受体的一类新的选择性配体。确定目标化合物的结合亲和力（使用放射性配体结合测定法）。与比较剂BP897相比，发现化合物2a和2c对D3受体表现出相当大的结合亲和力和选择性，尤其是化合物2h与BP897（正参比）具有相似的效力和更高的D3R配体。因此，它们可以为发现和开发具有出色选择性的高效多巴胺D3受体配体提供有价值的信息。
• Indolinone compounds as kinase inhibitors
  申请人：Sugen, Inc.

  公开号：US06689806B1

  公开（公告）日：2004-02-10

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

  这项发明涉及某些吲哚酮化合物，它们的合成方法，以及由该发明的吲哚酮化合物组成的组合式文库。该发明还涉及使用该发明的吲哚酮化合物调节蛋白激酶功能的方法，以及通过调节蛋白激酶功能和相关信号转导途径治疗疾病的方法。
• PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF
  申请人：ChoTang Peng Cho

  公开号：US20100075952A1

  公开（公告）日：2010-03-25

  The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

  该发明提供了由式(I)表示的新的吡咯基氮杂环衍生物或其盐，其制备方法，含有这种衍生物的药物组合物以及将这种衍生物用作治疗剂，特别是蛋白激酶抑制剂的用途，其中式(I)中的每个取代基与描述中定义的相同。
• Indolinone derivatives as protein kinase/phosphatase inhibitors
  申请人：——

  公开号：US20020052369A1

  公开（公告）日：2002-05-02

  The present invention relates to certain 2-indolinone compounds which modulate the activity of protein kinases (“PKs”) and phosphatases. The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及调节蛋白激酶（“PKs”）和磷酸酶活性的某些2-吲哚酮化合物。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗疾病的方法以及制备它们的方法。
• Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
  申请人：SUGEN, Inc.

  公开号：US20040186160A1

  公开（公告）日：2004-09-23

  The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.

  本发明涉及一类吲哚酮化合物，即六氢-环庚-吡咯酮氧吲哚，其作为蛋白激酶抑制剂具有用途。